Clinical Trial Update: A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression [Phase 3]

View source ↗

Summary

A Phase 3 study of mirvetuximab soravtansine in platinum-resistant, high-FRα epithelial ovarian, primary peritoneal, or fallopian tube cancers has completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• Elahere (mirvetuximab soravtansine)

Snippet

Sponsor: ImmunoGen, Inc. | Conditions: Epithelial Ovarian Cancer, Peritoneal Cancer | Phase 3 | Status: COMPLETED | Results posted: 2024-08-07